Alfonso MD - Tcr2 Therapeutics Chief Officer

Insider

Alfonso MD is Chief Officer of Tcr2 Therapeutics
Age 52
Phone617 949 5200
Webhttps://www.tcr2.com

Tcr2 Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.3473) % which means that it has lost $0.3473 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9146) %, meaning that it created substantial loss on money invested by shareholders. Tcr2 Therapeutics' management efficiency ratios could be used to measure how well Tcr2 Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Tcr2 Therapeutics currently holds 58.23 M in liabilities with Debt to Equity (D/E) ratio of 0.29, which may suggest the company is not taking enough advantage from borrowing. Tcr2 Therapeutics has a current ratio of 4.92, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Tcr2 Therapeutics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Mark MDPassage Bio
60
Clare MBAAlector
N/A
MS MBAADC Therapeutics SA
52
Erica JeffersonAlector
N/A
Denise MuellerAffimed NV
55
Lisa SkeltonADC Therapeutics SA
53
Stephen EvansfrekeADC Therapeutics SA
68
Simona KingPassage Bio
52
Dr DPHILADC Therapeutics SA
65
Desiree DDSPassage Bio
N/A
Thomas RinderknechtADC Therapeutics SA
67
Richard OnyettADC Therapeutics SA
73
David PomplianoRevolution Medicines
N/A
Julie DeSanderAgenus Inc
N/A
Christopher RobertsBlack Diamond Therapeutics
54
Robert SchmidtADC Therapeutics SA
43
Susan RomanusADC Therapeutics SA
59
TaiAn LinBlack Diamond Therapeutics
N/A
Peter GreaneyADC Therapeutics SA
41
Stephane HenchozADC Therapeutics SA
N/A
Walter ReiherRevolution Medicines
N/A
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor therapies for patients suffering from cancer. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Tcr2 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 105 people. Tcr2 Therapeutics (TCRR) is traded on NASDAQ Exchange in USA and employs 58 people.

Management Performance

Tcr2 Therapeutics Leadership Team

Elected by the shareholders, the Tcr2 Therapeutics' board of directors comprises two types of representatives: Tcr2 Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tcr2. The board's role is to monitor Tcr2 Therapeutics' management team and ensure that shareholders' interests are well served. Tcr2 Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tcr2 Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Angela Justice, Chief Officer
Patrick Baeuerle, Founder Board
Richard Roomberg, VP Controller
Dr MBA, CEO Pres
Margaret JD, Head Sec
Rosemary Harrison, Chief Officer
Peter Olagunju, Chief Officer
Alfonso MD, Chief Officer
Carl Mauch, Sr Communications
Eric CPA, Chief Officer

Tcr2 Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tcr2 Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Tcr2 Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tcr2 Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tcr2 Therapeutics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Ralph Lauren could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ralph Lauren when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ralph Lauren - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ralph Lauren Corp to buy it.
The correlation of Ralph Lauren is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ralph Lauren moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ralph Lauren Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ralph Lauren can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Other Consideration for investing in Tcr2 Stock

If you are still planning to invest in Tcr2 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tcr2 Therapeutics' history and understand the potential risks before investing.
Commodity Directory
Find actively traded commodities issued by global exchanges
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance